US FDA: Recommend "thyroid monitoring" for infants and young children receiving iodinated contrast agents

Compiled and organized by Yimaitong, please do not reprint without authorization
.

Recently, the US Food and Drug Administration (FDA) official website issued a notice: It is recommended that neonates and children under 3 years of age undergo thyroid follow-up monitoring within 3 weeks after receiving iodinated contrast injection
.

Based on recently published retrospective studies
.

The thyroid is a gland in the neck that releases hormones that help control many functions of the body
.

Retrospective studies suggest that underactive thyroid or a temporary drop in thyroid hormone levels is rare
.

However, when needed, these conditions should be detected and treated early to prevent potential future complications
.

Newborns, especially those born prematurely, and children with underlying medical conditions such as heart disease in the first three years of life are at higher risk for thyroid disease
.

Prior to this, the FDA has issued a warning on prescribing information for all classes of iodinated contrast injections and monitoring recommendations for children 3 years and younger
.

This warning describes the risk of underactive thyroid or a temporary drop in thyroid hormone levels
.

These risks and recommendations are associated with the administration of iodinated contrast media via arterial or intravenous administration
.

Yimaitong compiled from: FDA.
FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging Children with underlying conditions and newborns at higher risk[EB/OL].
[2022-4- 7].
https://